| Number of organ systems affected by SLE before PRCA diagnosis | Not applicable | 6 | 6 | 4 | 7 |
| Number of organ systems affected by SLE at PRCA diagnosis | Not applicable | 1 | 1 | 1 | 6 |
| Number of organ systems affected by SLE until last assessment | 3 | 3 | 5 | 1 | 2 |
| Haemoglobin levels at PRCA diagnosis (g/dl) | 7 | 4.9 | 4.9 | 4.5 | 6.3 |
| Bone Marrow biopsy or aspirate | Selective aplasia/hypoplasia of the red series, without changes in other series |
| SLEDAI / SLICC-ACR DI at PRCA diagnosis | Not applicable | 4 / 1 | 2 / 1 | 0 / 0 | 20 / 0 |
| SLEDAI / SLICC-ACR DI 1 year after PRCA | Not applicable | 0 / 1 | 2 / 1 | 2 / 0 | 4 / 0 |
| SLEDAI / SLICC ACR DI at last assessment | 0 / 0 | 6 / 3 | 0 / 2 | 0 / 0 | 0 / 0 |
| Number of treatment lines | 2 | 2 | 2 | 1 | 4 |
| Treatments administered | 1st: Oxitosona | 1st: Glucocorticoids | 1st: Glucocorticoids | Glucocorticoids | 1st: Glucocorticoids hydroxicloroquine | 2nd: Belimumab erythropoietin |
| 2nd: Inmunoglobulins | 2nd: Inmunoglobulins & RBC transfusion | 2nd: Ciclosporin A | | 3rd: Rituximab | 4th: Darbepoetin α |
| Total number of treatments administered | 2 | 3 | 2 | 1 | 6 |
| Relapse | No |
| Death | No |